You are here: Home » Current Affairs » Coronavirus » News
Business Standard

Bangladesh approves getting 30 mn doses of Covishield vaccine from India

Bangladesh approved procurement of 30 million doses of Covishield Covid-19 vaccine from India, co-developed by European pharmaceutical company AstraZeneca and Oxford University

Coronavirus Vaccine | Bangladesh | India


AstraZeneca wasn't the obvious choice to partner up with Oxford when scientists there started developing a coronavirus shot. Photographer: Mikael Sjoberg/Bloomberg
Covid-19 vaccine

on Thursday approved procurement of 30 million doses of Covishield COVID-19 vaccine from India, co-developed by European pharmaceutical company AstraZeneca and Oxford University.

drug regulator Directorate General of Drug Administration (DGDA) has authorised Beximco Pharmaceuticals Limited to import and distribute the COVID-19 vaccine from In the initial six months of the first phase, Beximco will procure five million vaccine doses per month, reported Dhaka Tribune.

"Beximco pharma can now import and distribute the COVID-19 vaccine from It will first supply the vaccine in meeting the government's requirements. Then it can supply the vaccine to private hospitals approved by the government," said DGDA Deputy Director Md Salauddin.

Earlier on Monday, the government issued a no-objection certificate (NOC) on emergency use of the Oxford-AstraZeneca COVID-19 vaccine. After the UK authorized the vaccine on Wednesday, India's drug regulator on Friday approved the vaccine for emergency use, reported Dhaka Tribune.

The Serum Institute of (SII) is the local manufacturer of the Oxford-AstraZeneca Covid-19 vaccine.

Earlier, in November, signed an agreement with the SII, through which Beximco Pharma will avail 30 million doses of the vaccine.

Additionally, the DGDA on Wednesday approved for clinical trial Globe Biotech Limited's manufacture of its Covid-19 vaccine, Bongavax, reported Dhaka Tribune.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Fri, January 08 2021. 09:45 IST